| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 228,390 | 233,260 | 237,280 | 222,610 | 78,700 |
| Sales Growth | -2.09% | -1.69% | +6.59% | +182.86% | +131.88% |
| Net Income | -114,760 | -99,590 | -37,330 | -275,530 | -32,690 |
| Net Income Growth | -15.23% | -166.78% | +86.45% | -742.86% | -78.34% |
Cryoport Inc (CYRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
CryoPort, Inc. operates as a provider of shipping solutions comprising cold chain frozen shipping system for transporting biological, environmental and other temperature sensitive materials at temperatures below minus 150' Celsius. Its products include CryoPort Express Shippers, cryogenic dry vapor shippers capable of maintaining cryogenic temperatures; biological material holders for the shipment of infectious or dangerous goods; CryoPort Express System to programmatically manage order entry and various aspects of shipping operations; and CryoPort Express Analytics, to monitor shipment performance metrics and to evaluate temperature-monitoring data collected by the data logger during shipment. The Company's products find their application in the transportation of live cell pharmaceutical products, such as cancer vaccines, diagnostic materials, semen and embryos, and infectious substances. CryoPort, Inc. is based in Lake Forest, California.
Fiscal Year End Date: 12/31